Saghir Ali

Inhalable Psychedelic 5-MeO-DMT Shows Promise in Treatment-Resistant Depression

Saghir Ali, Xiaochen Tian, Noelle C. Anastasio, Kathryn A. Cunningham et autres

Treatment-resistant depression (TRD) is defined as the failure to achieve a clinically significant improvement in major depressive disorder (MDD) despite treatment with at least two different standard antidepressants administered at adequate doses duration.1 TRD significantly impairs daily functioning and imposes a considerable …

us (code pays fourni par la source)

Drug Discovery of Allosteric Molecular Glue Degraders (aMGDs): Expanding the Landscape of Targeted Protein Degradation

Yu Xue, Saghir Ali, Haiying Chen, Jia Zhou

us (code pays fourni par la source)

FDA Approval of the First-Ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation

Anil Kumar, Saghir Ali, Qiang Shen, Jia Zhou

Targeted protein degradation (TPD), including proteolysis targeting chimeras (PROTACs) and molecular glues (MGs), has emerged as a promising therapeutic strategy with significant potential to selectively eliminate disease-causing proteins that have traditionally been intractable to conventional small molecules therapeutics.1,2 Over the past two …

us (code pays fourni par la source)

Discovery of Small Molecule Ligands Targeting Orphan G Protein-Coupled Receptors GPR3, GPR6, and GPR12

Xiaochen Tian, Saghir Ali, Jones Addiah-Nickson, Haiying Chen et autres

GPR3, GPR6, and GPR12 form a subfamily of Class A orphan G protein-coupled receptors (oGPCRs), for which endogenous ligands have not been identified. Despite their high sequence similarity, each receptor exhibits unique expression profiles in human tissues. Their physiological roles and therapeutic …

us (code pays fourni par la source)

Artificial intelligence revolutionizing CNS drug discovery and development

Md E.K. Talukder, Mohammad R. Islam, Saghir Ali, Jia Zhou et autres

us (code pays fourni par la source)

CVN-424: An Advanced GPR6 Inverse Agonist in Phase III Clinical Trials for Parkinson’s Disease

Xiaochen Tian, Saghir Ali, John A. Allen, Jia Zhou

us (code pays fourni par la source)

Prevalence of Halogens in 2025 FDA-Approved Drugs: Highlight on Suzetrigine, the First Nonopioid Painkiller in Decades

Saghir Ali, Cun Zhang, Jia Zhou

Halogens are widely recognized as privileged functionalities for modulating the biological and physicochemical properties of small molecule drugs and have firmly established their place in the medicinal chemist's toolbox.A survey of the literature reveals that about 25% of FDA-approved small molecule drugs …

us (code pays fourni par la source)

Key contemporary considerations for halogens in drug discovery

Saghir Ali, Jia Zhou

Halogens (F, Cl, Br, I), especially F and Cl play a vital role in contemporary drug discovery. For instance, around 25% of approved drugs and 40% of lead molecules possess halogens [1]. Moreover, m...

us (code pays fourni par la source)

A New Era of Artificial Intelligence (AI): Transforming Drug Discovery and Development

Saghir Ali, Xiaochen Tian, Haiying Chen, Jia Zhou

us (code pays fourni par la source)

Old Dog, New Tricks: Ibogaine and Its Analogs as Potential Neurotherapeutics

Saghir Ali, Xiaochen Tian, Kathryn A. Cunningham, Jia Zhou

us (code pays fourni par la source)

Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond

Saghir Ali, Xiaochen Tian, Kathryn A. Cunningham, Jia Zhou

us (code pays fourni par la source)

Highlights on U.S. FDA-approved halogen-containing drugs in 2024

Saghir Ali, Xiaochen Tian, Salvatore A Meccia, Jia Zhou

us (code pays fourni par la source)